Aclaris Therapeutics, Inc. (ACRS) SEC Filing 10-Q Quarterly report for the period ending Friday, March 31, 2017

Earnings Press Release
10-Q Quarterly Report
10-Q QoQ Changes
Aclaris Therapeutics, Inc.
Ticker: ACRS CIK: 1557746

Exhibit 99.1

Aclaris New Logo

Aclaris Therapeutics Reports First Quarter 2017 Financial Results

Management to Host Conference Call at 4:30 PM ET today

Malvern, PA – May 9, 2017 (GLOBE NEWSWIRE) –

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biotechnology company, today announced financial results for the first quarter of 2017 and provided an update on its clinical development programs.

“The start of 2017 has been a busy one for Aclaris and we are pleased the momentum from last year has continued into the first quarter of this year,” commented Dr. Neal Walker, President and Chief Executive Officer of Aclaris. “Our New Drug Application (NDA) for A-101 40% Topical Solution (A-101 40%) for the treatment of seborrheic keratosis (SK) was accepted for review by the U.S. Food and Drug Administration (FDA). We continue to advance our pipeline and broaden our intellectual property estate as we focus our efforts on developing innovative treatments for patients.”

Clinical Pipeline Update

A-101 40% Topical Solution

The NDA for A-101 40% for the topical treatment of SK has been accepted by the FDA for review.

The NDA contains data from three Phase 3 trials that included more than 1,000 patients.

Plan to submit a marketing authorization application (MAA) for A-101 40% for the treatment of SK in the European Union in the second half of 2017.

A-101 45% Topical Solution

Plan to initiate two Phase 2 clinical trials of A-101 45% Topical Solution (A-101 45%) for the treatment of common warts in mid-2017.

JAK Inhibitor

Recently completed a Phase 1 clinical trial of ATI-50001, an investigational oral Janus Kinase (JAK) 1/3inhibitor. This Phase 1 cross-over trial was conducted in 12 healthy volunteers at one investigational center in the United States to assess safety, bioavailability, and pharmacodynamics.

In the Phase 1 trial, treatment with ATI-50001 capsules was well tolerated. No clinically significant laboratory abnormalities were observed. These data are consistent with results from an earlier Phase 1 clinical trial in 44 healthy volunteers conducted by Rigel Pharmaceuticals in which the study drug was well tolerated at all doses.

Plan to initiate a Phase 2 dose ranging trial with ATI-50001 for the oral treatment of alopecia totalis and alopecia universalis in the second half of 2017.

In addition, Aclaris also plans to develop an investigational topical JAK 1/3inhibitor, known as ATI-50002, for the treatment of AA and vitiligo.

Plan to submit an Investigational New Drug application (IND) for ATI-50002 for the topical treatment of patchy AA in mid-2017.

The following information was filed by Aclaris Therapeutics, Inc. (ACRS) on Tuesday, May 9, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Aclaris Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Aclaris Therapeutics, Inc..

Continue

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1557746/000155837017004000/acrs-20170331x10q.htm